Xenova Phase II herpes failure

XNVA (LSE:XEN; XNVA) said its TA-HSV therapeutic vaccine was not effective compared to placebo in a placebo-controlled Phase II study of 483 HSV-2 seropositive patients with symptomatic recurrent geni...